TMC207 is a first-in-class anti-TB diarylquinoline (also named R207910 or the 'J' compound) with activity against drug-sensitive and drug-resistant TB. TMC207 inhibits the proton pump of ...

[11] Because the elderly are more vulnerable to drug-induced AKI and usually have poor renal recovery, [14,15] AKI during anti-TB treatment may be more common and serious in Taiwan, where more ...

Sydney researchers have found that Levofloxacin substantially reduces risk of drug-resistant tuberculosis. This discovery offers new hope against a disease that infects more than 400,000 people ...

Tuberculosis (TB) is the world’s biggest infectious disease killer with multidrug-resistant TB (MDR-TB) posing a particular ...

The Health Ministry has dismissed media reports claiming a shortage of anti-tuberculosis (TB) drugs in India, labelling them as "incorrect and misleading". In a statement, the Ministry emphasised ...

Researchers continue to seek better alternatives. The first anti-TB drug, streptomycin, was developed in 1944, but TB has always required at least two strong antibiotics to defeat it. And ...

Most bacteria have few, if any, P450s but we discovered that the TB bacterium has 20 different types." Even more exciting for the team was the knowledge that existing anti-fungal drugs already target ...

Day.The World Health Organisation estimates that a quarter of the world’s population is infected with latent TB, of which 10 ...

Multidrug resistant tuberculosis (MDR-TB) is a serious, life-threatening illness with evolving treatment regimens for better ...

TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections. TaBriX’s initial focus is on the ...